Previous 10 | Next 10 |
home / stock / aspcf / aspcf news
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three- and nine-month period ended September 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accor...
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB :ASPCF) will announce its third quarter 2019 financial and operating results on Thursday, November 14, 2019 before the market opens. The company will also host a conference call on Thursday, November 14, 2019 at 8:30 a.m. Eastern Time. To...
Current NATESTO ® supply to the United States remains unaffected Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO ® in Canada and South Korea, following the previous announcement of the voluntary...
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the expanded use of NATESTO ® for the treatment of hypogonadism on Wednesday, October 30 th in New York City. The ev...
NATESTO ® shown to significantly increase mean testosterone levels, while maintaining sufficient gonadotropins to preserve fertility Improvement in quality-of-life, overall satisfaction and sexual desire was reported Approximately 65% of men become infertile when presc...
TORONTO , Oct. 17, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO ® Spermatogenesis Study as part of the "Late Breaking" Abstract Session at the 75th Annual American Society for Reproductive ...
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter f...
Acerus Pharmaceuticals Corporation (ASPCF) Q2 2019 Earnings Conference Call August 7, 2019 8:30 A.M. ET Company Participants Robert Motz - Chief Financial Officer Edward Gudaitis - President and Chief Executive Officer Conference Call Participants André Uddin - Mackie Re...
Acerus Pharmaceuticals ( OTCQB:ASPCF ): Q2 GAAP EPS of -$0.01. More news on: Acerus Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance w...
News, Short Squeeze, Breakout and More Instantly...
Acerus Pharmaceuticals Corp Company Name:
ASPCF Stock Symbol:
OTCMKTS Market:
Acerus Pharmaceuticals Corp Website:
TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) and its subsidiaries were granted creditor protection pursuant to an order (the “ Initial Order ”) g...
TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “ Acerus ”) were granted protection pursuant to an order (the “ Initial Order ”) issued under the Companies ...
TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA,...